Volume 91, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Chagas disease is a neglected vector-borne disease with an estimated prevalence of 1.1 million cases in Mexico. Recent research showed that access to treatment of Chagas disease is limited in Mexico, with < 0.5% of infected cases treated. This brief report used quantitative data from the Morelos Program on Chagas disease and qualitative analysis of key informant interviews to examine strategies to increase treatment access for infected patients in Morelos, Mexico. From 2007 to 2011, 263 (9.2%) of the registered cases of Chagas disease in Mexico occurred in Morelos. Among these, 152 (57.8%) were treated and 97.3% of those treated received benznidazole. The assessment finds that state officials decided to directly purchase benznidazole from the distributor to increase access and improve clinical quality of treatment of patients in their state. They also faced significant barriers, especially in regulation and health system organization, which limited efforts to make high quality treatment available.


Article metrics loading...

Loading full text...

Full text loading...



  1. Mathers CD, Ezzati M, Lopez AD, , 2007. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis 1: e114.[Crossref]
  2. Pan American Health Organization, 2006. Estimacion cuantitativa de la enfermedad de Chagas en las Americas. Montevideo, Uruguay: WHO Department of Control of Neglected Tropical Diseases.
  3. Ramsey JM, Elizondo-Cano M, Sanchez-Gonzalez G, Pena-Nieves A, Figueroa-Lara A, , 2014. Opportunity cost for early treatment of Chagas disease in Mexico. PLoS Negl Trop Dis 8: e2776.[Crossref]
  4. Manne JM, Snively CS, Ramsey JM, Salgado MO, Barnighausen T, Reich MR, , 2013. Barriers to treatment access for Chagas disease in Mexico. PLoS Negl Trop Dis 7: e2488.[Crossref]
  5. Comision Nacional de Proteccion Social en Salud, 2011. Seguro Popular Catalogo Universal de Servicios de Salud Secretaria de Salud - Estados Unidos Mexicanos.
  6. Consejo de Salubridad General, 2010. Cuadro Basico y Catalogo de Medicamentos. Mexico, D.F.: Comisión Interinstitucional del Cuadro Básico de Insumos del Sector Salud.
  7. Roberts MJ, Reich MR, , 2011. Pharmaceutical Reform: A Guide to Improving Performance and Equity. Washington, DC: The World Bank.[Crossref]
  8. Guzman-Bracho C, , 1998. Risk of transmission of Trypanosoma cruzi by blood transfusion in Mexico. Rev Panam Salud Publica 4: 9499.[Crossref]
  9. Attaran A, , 2006. Chagas' disease in Mexico. Lancet 368: 1768; discussion 1768–1769.[Crossref]
  10. Ocampo-Salgado M, , 2012. Tratamientos Chagas 2006–2012 SSM. Morelos, Mexico.
  11. Comision Federal Para la Proteccion Contra Riesgos Sanitarios, 2010. Comprobante de Tramite (COFEPRIS-01-010-C). Mexico: Secretaria de Salud.
  12. Masters Pharmaceuticals Limited Ltd., 2010. Invoice 03O6010-03 (Benznidazol). Hertfordshire, UK: Masters Pharmaceuticals Limited Ltd.
  13. Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, Roddy P, Parreno F, Albajar Vinas P, Palma PP, , 2009. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis 3: e488.[Crossref]
  14. Moise PD, , 2007. Pharmaceutical Pricing and Reimbursement Policies in Mexico. Paris, France: Organization for Economic Cooperation and Development.[Crossref]
  15. Ramsey JM, , 2007. Chagas disease transmission in Mexico: a case for translational research while waiting to take disease burden seriously. Salud Publica Mex 49 (Suppl 1): 291295.

Data & Media loading...

  • Received : 09 Jun 2014
  • Accepted : 06 Aug 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error